PCSK9 and diabetes mellitus: Finally, human genetic analyses supported the long-term safety of PCSK9 inhibition (and the low levels of plasma LDL-C that would be achieved), mitigating concerns of adverse neurocognitive effects, incident diabetes, and other potential liabilities (18), concerns which have been further alleviated with data from large randomized controlled trials and long-term use of approved PCSK9 inhibitors (19).